ID   MUTZ-3
AC   CVCL_1433
SY   Mutz-3; MUTZ3; Mutz3; Menschliche Und Tierische Zellkulture-3
DR   CLO; CLO_0007903
DR   EFO; EFO_0005395
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473344
DR   BioSample; SAMN10989596
DR   Cell_Model_Passport; SIDM01873
DR   Cosmic; 787462
DR   Cosmic; 975281
DR   Cosmic; 1012102
DR   Cosmic; 1281338
DR   Cosmic; 2306224
DR   Cosmic; 2378088
DR   Cosmic; 2733530
DR   DepMap; ACH-000084
DR   DSMZ; ACC-295
DR   GEO; GSM305093
DR   GEO; GSM305094
DR   GEO; GSM305095
DR   GEO; GSM801964
DR   GEO; GSM1374693
DR   GEO; GSM2037138
DR   GEO; GSM2037139
DR   LiGeA; CCLE_080
DR   Lonza; 53
DR   PharmacoDB; MUTZ3_970_2019
DR   Wikidata; Q54907100
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   Patent=US9029143;
RX   PubMed=8667638;
RX   PubMed=9096695;
RX   PubMed=12091369;
RX   PubMed=16408098;
RX   PubMed=16423051;
RX   PubMed=17533051;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=31068700;
RX   PubMed=31160637;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line.
CC   Doubling time: ~110 hours (DSMZ); 90-110 hours, in presence of supernatant of 5637 (CVCL_0126) cells (PubMed=8667638).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly10_Ala11insGly (c.31_32insGAG); Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: H3K79me1 ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 8,12
ST   D16S539: 12
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C82426; Acute myeloid leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2) GATA2, MECOM
DI   ORDO; Orphanet_402020; Acute myeloid leukemia with inv3(q21;q26.2) or t(3;3)(q21;q26.2)
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 26
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   Patent=US9029143;
RA   Goletz S., Scheper R.J., Masterson A.J., Pinedo H.M.;
RT   "MUTZ-3 dendritic cells.";
RL   Patent number US9029143, 15-May-2015.
//
RX   PubMed=8667638;
RA   Hu Z.-B., Ma W., Zaborski M., MacLeod R.A.F., Quentmeier H.,
RA   Drexler H.G.;
RT   "Establishment and characterization of two novel cytokine-responsive
RT   acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3.";
RL   Leukemia 10:1025-1040(1996).
//
RX   PubMed=9096695; DOI=10.1038/sj.leu.2400621;
RA   Drexler H.G., Zaborski M., Quentmeier H.;
RT   "Thrombopoietin supports the continuous growth of cytokine-dependent
RT   human leukemia cell lines.";
RL   Leukemia 11:541-551(1997).
//
RX   PubMed=12091369; DOI=10.1182/blood.V100.2.701;
RA   Masterson A.J., Sombroek C.C., de Gruijl T.D., Graus Y.M.F.,
RA   van der Vliet H.J.J., Lougheed S.M., van den Eertwegh A.J.M.,
RA   Pinedo H.M., Scheper R.J.;
RT   "MUTZ-3, a human cell line model for the cytokine-induced
RT   differentiation of dendritic cells from CD34+ precursors.";
RL   Blood 100:701-703(2002).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16423051; DOI=10.1111/j.1365-2567.2005.02274.x;
RA   Larsson K., Lindstedt M., Borrebaeck C.A.;
RT   "Functional and transcriptional profiling of MUTZ-3, a myeloid cell
RT   line acting as a model for dendritic cells.";
RL   Immunology 117:156-166(2006).
//
RX   PubMed=17533051; DOI=10.1016/j.exphem.2007.03.003;
RA   Ciraci E., Barisani D., Parafioriti A., Formisano G., Arancia G.,
RA   Bottazzo G., Berardi A.C.;
RT   "CD34 human hematopoietic progenitor cell line, MUTZ-3, differentiates
RT   into functional osteoclasts.";
RL   Exp. Hematol. 35:967-977(2007).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//